7 May 1999
A subsidy of the Swiss multinational pharmaceutical company, Serono Laboratories, is understood to be the front-runner for Bedfont Cross, the 1,810 sq m (19,500 sq ft) Welbeck Land scheme completed at the end of February.
You must be logged in to continue
Register for free to finish this article
Registration includes the following benefits:
To access this article REGISTER NOW
Four articles not enough? SUBSCRIBE for unlimited access to over 100 weekly articles and our comprehensive archive. For as little as £5 per week.